☆ 4.7 Editorial Material

Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study Comment

LANCET ONCOLOGY (2022)

Systemic treatment of hepatocellular carcinoma: An EASL position paper

Jordi Bruix et al.

Summary: Significant advances have been made in the systemic treatment of hepatocellular carcinoma in the last 5 years, with new drugs and treatment strategies emerging. Prolonged survival exceeding 2 years is expected in most patients, and selecting the right medication based on patient characteristics and preferences is crucial for sound therapeutic decisions.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot

Jordi Bruix

Summary: Clinical trials rely on strict definitions and criteria, but real-world clinical practice may not follow the same guidelines, leading to discrepancies in patient selection, disease assessment, and treatment decisions. Understanding these differences is crucial in refining criteria for drug activity, toxicity, and treatment failure in order to achieve evidence-based clinical practice and precision oncology.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Insights into the success and failure of systemic therapy for hepatocellular carcinoma

Jordi Bruix et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Postprogression Survival of Patients With Advanced Hepatocellular Carcinoma: Rationale for Second-Line Trial Design

Maria Reig et al.

HEPATOLOGY (2013)

添加到收藏夹

Editorial Material Oncology

Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care

R. Peto

BRITISH JOURNAL OF CANCER (2011)

添加到收藏夹

Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study Comment

相关参考文献

Systemic treatment of hepatocellular carcinoma: An EASL position paper

Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Insights into the success and failure of systemic therapy for hepatocellular carcinoma

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Postprogression Survival of Patients With Advanced Hepatocellular Carcinoma: Rationale for Second-Line Trial Design

Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care

导出引文

分享论文